Global prevalence of metabolic syndrome among patients with type I diabetes mellitus: a systematic review and meta-analysis

Belete, Rebuma; Ataro, Zerihun; Abdu, Ahmedmenewer; Sheleme, Merga

doi:10.1186/s13098-021-00641-8

Table 2 Characteristics of studies included for systematic review and meta-analysis

From: Global prevalence of metabolic syndrome among patients with type I diabetes mellitus: a systematic review and meta-analysis

Authors	Country	Design	DM duration^a (in years)	Age^a (in years)	Study participants^b	Diagnostic criteria	MetS cases	Prevalence (%)			Quality rating (NOS)
Authors	Country	Design	DM duration^a (in years)	Age^a (in years)	Study participants^b	Diagnostic criteria	MetS cases	Overall	Male	Female	Quality rating (NOS)
Ahola et al. [20]	Finland	CS	NR	45 ± 13.5	791	JIS	452	57.1	80.7	56.2	Moderate
Barros et al. [29]	Brazil	CS	15.5 ± 9.3	30 ± 12	1662	IDF	469	28.2	19.8	35.1	High
Billow et al. [44]	India	CS	NR	15.37 ± 13.5	451	JIS	100	22.2	22.8	21.3	Moderate
Blaslov et al. [27]	Croatia	CS	22.17 ± 11.7	45.08 ± 11.87	77	IDF	26	33.8	36.2	30.0	Moderate
Bonadonna et al. [36]	Italy	CS	16 ± 11	48 ± 17	638	IDF	260	40.8	34.1	47.4	Moderate
Chillarón et al. [7]	Spain	CS	16.7 ± 12.9	39.7 ± 13.2	91	Modified NCEP	29	31.9	32.1	31.6	High
Davis et al. [30]	Australia	Cohort	NR	42.0 ± 15.7	127	IDF	50	39.4	NR	NR	High
Ferreira-Hermosillo et al. [48]	Mexico	CS	17 (11–25)	28 (22–37)	140	JIS	61	44.0	NR	NR	Moderate
Ghosh et al. [41]	Scotland	CS	19.04 ± 12.9	43.78 ± 18.9	365	WHO	112	30.7	56.3	19.4	Moderate
Hawa et al. [49]	Europe countries^c	CS	18.2 ± 11.7	43.8 ± 9.8	288	NCEP	92	31.9	NR	NR	High
Huo et al. [31]	China	CS	4 (1–8)	16 (9–28)	754	IDF	76	9.0	7.5	12.5	Moderate
Kilpatrick et al. 2007 [32]	USA	Cohort	NR	26.5 ± 7.5	1337	IDF	291	21.7	NR	NR	High
Köken et al. [33]	Turkey	CS	4.6 ± 3.3	13.8 ± 2.8	200	IDF	21	10.5	NR	NR	Moderate
Lee et al. 2020 [50]	Australia	CS	18.5 ± 12.5	44.3 ± 15.6	2120	WHO	643	30.0	31.8	28.5	High
Łuczyński et al. 2011 [19]	Poland	CS	4.4 (2.1–7.0)	13.6 (10.2–15.9)	500	IDF	16	3.2	NR	NR	Moderate
McGill et al. [43]	Australia	CS	NR	NR	427	WHO	64	15.0	NR	NR	High
Merger et al. [28]	Germany/Austria	Cohort	15.66 ± 13.1	38.36 ± 18.7	31,119	NCEP	7926	25.5	25.8	25.0	Moderate
Mollo et al. [51]	Spain	CS	0.8(0.5–3.25)	45.5 ± 11.9	78	NCEP	11	15.5	NR	NR	Moderate
Nádas et al. [34]	Hungary	CS	18.0 ± 11.1	35.6 ± 11.6	533	IDF	193	36.2	32.8	39.4	High
Pambianco et al. [35]	USA	Cohort	NR	NR	514	IDF	43	8.0	2.7	12.7	High
Rodrigues et al.[52]	Brazil	CS	16.5 ± 9	34.8 ± 11	261	NCEP	35	13.4	10.9	16.1	Moderate
Saki [37]	Iran	CS	4.4 ± 2.8	12.38 ± 4.2	87	IDF	26	29.9	25.6	22.9	Moderate
Santos et al. [38]	Brazil	CS	16.8 ± 10	32.5 ± 10	101	IDF	32	32.0	NR	NR	Moderate
Soliman et al. [8]	Egypt	CS	5.74 ± 3	13.38 ± 2.17	160	IDF	21	13.1	7.8	18.1	Moderate
Szadkowska et al. [39]	Poland	CS	6.2 ± 4.2	14.8 ± 2.4	163	IDF	12	7.4	6.6	8.3	Moderate
Thorn et al. [53]	Finland	CS	21.9 ± 1.8	37.2 ± 1.3	2415	NCEP	944	39.1	38.2	40.1	Moderate
Valerio et al. [40]	Italy	CS	8.4 ± 3.9	17.3 ± 0.9	412	IDF	39	9.5	3.7	16.1	High

N: number of T1DM patients participated in the study; MetS: metabolic syndrome; NOS: Newcastle Ottawa Scale; T1DM: Type 1 diabetes mellitus; DM: diabetes mellitus; CS: cross-sectional; NECP: National Cholesterol Education Program Expert Panel; IDF: International Diabetes Federation; WHO: World Health Organization; JIS: Joint Interim Statement; NR: Not Reported; NA: not applicable;
^aData are in mean (± standard deviation) or median (inter quartile range); ^b only T1DM patients; ^cIreland, France, Spain, Italy and England;

Back to article page

ISSN: 1758-5996

Contact us

Submission enquiries: journalsubmissions@springernature.com

Diabetology & Metabolic Syndrome

Contact us